- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Salix Pharmaceuticals introduces Rx topical foam to treat a form of inflammatory bowel disease
PARIS — An investigational drug helped patients survive longer when combined with chemotherapy as a second-line treatment for colorectal cancer that had spread to other parts of the body, according to results of a late-stage clinical trial announced by French drug maker Sanofi-Aventis and U.S.-based Regeneron Pharmaceuticals.
The phase-3 trial combined the drug Zaltrap (aflibercept) with a combination of the chemotherapy drugs folinic acid (leucovorin), 5-fluorouracil and irinotecan, also known as the FOLFIRI regimen.
“We are pleased with the results of the Zaltrap phase-3 study in this group of patients,” stated Debasish Roychowdhury, SVP and head of Sanofi-Aventis’ global oncology division. “We are committed to bringing Zaltrap to patients with advanced colorectal cancer and maximizing the therapeutic potential of this unique and exciting medicine.”